This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): HSPPC-96, Vitespen, G-200
Description: BioMedTracker has separate drug profiles for vitespen. Please also see Oncophage.
Oncophage is a personalized vaccine designed to treat cancer while minimizing side effects. It utilizes a proprietary heat shock protein technology in which antigens and heat shock proteins (HSP) from the patient's own tumor cells are isolated. This mixture of antigens and HSP is then re-introduced to the patient as a vaccine to stimulate the patient's immune system to fight the tumor from which the proteins were derived.
Additional information available to subscribers only: